X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims for the development of the first oral formulation of ArsciCor (arsenic troxide) in the field of several targeted autoimmune diseases, including for cGvHD treatment.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: ArsciCor
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BioSenic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 15, 2024
Details:
Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: OATO
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Medsenic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 29, 2023
Details:
Exclusive licensing agreement for the development of a patented formulation of oral arsenic trioxide in the treatment of autoimmune diseases. Initially the oral formulation of arsenic trioxide will target the treatment of patients with chronic graft-versus-host disease.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Medsenic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
